COMISSÃO DE SAÚDE

Thank you. Good morning to all. and all present. I thank the Health Commission of the Câmara of Deputies for promoting this debate, to the deputado Jorge Sola for being presiding this audience, for having proposed this topic, and to my predecessors, my director Igor Bueno and the assessor of Fiocruz, João Miguel, because his talks Jack. they already brought content that I would adopt in my talk. I wanted to ask the people I will put my presentation. Well, while I'm putting the presentation... I was invited to the Bahia Farma, but I wanted to remind the deputy George Sola that I also am director of the Office of Laboratories Public Officials, the FOB. And in that condition I also participate in this... of this public audience. To say that the Bahia Farma is in frank reconstruction, the Bahia Farma has always been of the 24 pharmaceutical laboratories that exist in Brazil, She was already a producer of for tuberculosis and rancenia, a big production. She was, in 1996, a Bahia-Farmac was extinta and returned in 2011, in the office of the secretary George Sola and the governor Jacques Wagner. The Bahia Farma, the reconstruction of Bahia Farma, the government of Bahia is aposting on this public policy of the economic and industrial health and the PAC, with the return of this with the government Lula, and also with investments in the order of 157 million dollars in our Baía Farma's plants, which is a modernization of plants and diagnostic kits. Can you pass the next one, please? Well, Igor said that the PDP is a public health program very important for transfer of technology, for the sovereignty of Brazil in the area of medical and pharmaceuticals, but it is reged by a port. And Igor said well what it prevails, transfer of technology, production national and reducing progress of prices, which is what has been a with these PDPs, as already shown by João. Can you move on to the next one? Thank you. The big challenge we have, as the deputy Jorge Sola said at the beginning of his speech, put very visible in the COVID-19 pandemic, total dependence of medical and insumos from the exterior. So, for the sustainability of the SUS, it is extremely important the growth of the public public laboratories, producing more medical and insumos and with reduction of prices, which is the practice of PDP. Okay. And we also have high cost medications, and these high cost medications our external dependence is still higher. And this impacts a lot on the budget, both municipals, state and federal health. Well, The last row of PDPs from the Ministry of Health, the Igor said also, received 104 projects of PDP, of vaccines, 12 vaccines, 4 approved, 18 medical biologists, 7 approved, 22 tests rapid, none approved, 12 accessories, 40 other medicines, of sólidos orais, soluções, colírios, 18 approved. So, from 104 projects of PDP submeted, Igor said that this shows that this shows that the that there is still a lack of these projects. 30 were approved for 17 products. We at Bahia Farma presented 15 projects of PDP and four were approved, 27% of our projects. Our PDPs approved were all in the Biological area. And I just want to... I would like to say that this represents a very important mark, which is bringing the production of medicals highly technological products to Bahia and the Nordeste of Brazil, since there is a big concentration in the big players public. of medicine, which is the Fiocruz, through Biomanguinhos and Farmanguinhos, and the Butantan in São Paulo. So this is a very important journey to bring the West to this very advanced medicine product. In the PDPs approved by us, There were four biological medical medicines, with two of them, from Samsung, which is a Korean company, and two of them from two companies two Indian companies, the BioCoin and Dr. Edges, and it's important to say that our national partner is a Bionovies, which is a company that was built for this strategy of PDPs, We have several PDPs in andamentos, with various laboratories, especially with biomanguinos. So, we have our PDPs approved, we approved the Eculizumab, which is for a rare disease, a hemoglobinuria paroxysmica noturna. And it's interesting that our proposal was with a reduction of more than 40% of the price that the Ministry compra, and it was the Bevacizumab, Nivolumab, Pertuzumab, which are medical oncology for various types of cancer. C cancer of coloretal, mama, pulmary, melanoma, etc. This has a very important impact, because these are the medicines that are on the border of the knowledge, are the most used for various types of cancer, has a huge impact, doing this treatment of high complexity in the SUS, increase the survival of the population, are high cost treatments and have a growth of demand I always... It's very big. So, the national production of this is extremely important to better and improve the assistance of these people. And the strategy of partnership is to transfer technology. So, we will receive the technology of these medications, but it's like João said, that this transfer means that our team will be ready to do it. and also research and research in this area, including other medicines. Can you pass the next one, please? One thing we also wanted to call attention, the President Jorge Sola, is another program that is a prime of the PBPs, which is what the João also has been talking about, but we need to increase the eyes on this program, because it is extremely important, which is the Parceries of Development and Inovação Local, to donate these laboratories to research units, to enter the research of new medicines. We know that there is a very big gap that is always talked about between what is developed in universities, in institutions of science and technology and for the production of these medications. And I asked him to make a bridge between these processes that are beginning research of medicines, to bring us to the public laboratories. We also had two important projects approved, which is a hydroxyurea, a hydroxyurea, a hydroxyurea is a oncologist, but he is used, he was used as oncologist, but he is used in Brazil for treatment of the false form. who has a false form, however, there is no formula pediatrics. The mothers have to manipulate the oncological medic for dilute and a dose that is not always necessary. So this development is very important. The false form is a very prevalent in Brazil, especially in the Bahia, in some other states also and developing this medicine is something important for the SUS and also for other countries, like the Africa, where there is a great prevalence of the false form. We put three projects to ask, we have two, and the other is a probiotic for treatment of neuropathia diabetes, which is also a very high prevalence in Brazil, and there is nothing to improve this neuropathia. This probiotic has already been proven that it improves these patients, and we are doing this development both the Hidroxuree and the Probiótico, with the UFBA, the UFBA, the UNEB, the University of Recôncavo, so it is also a possibility of partnership between the public laboratories and the universities. Can you pass? Well, what is the strategic importance of these projects? This was already said, but I think it's always good to repeat this. It's the decentralization of the competencies in biotechnology to the fortification of the health economic and economic development, the sustainability of the SUSE, with the promotion of the economy that the PDP she already proposes that the projects start with a lower price of the price of the ministry, and this goes down to the year, the productive, with technological autonomy, development of national technologies and strengthening the biotechnology production of the Northeast, which I already mentioned. And it's important to say that in the seara of biological medical medicine, only five countries in the world produce biological biologists and biosimilar, which are the United States, China, sorry, India, Korea-sul and Brazil. So we are, through the PDPs, leading this technology to the Nordeste of Brazil. Excellent. Sorry, I'm sorry. Also, the access and security, as we already said. Now, here is a moment the deputy Josi Sola, Igor, João, we also discuss the problems of the PDPs, which is a policy that is a policy adolescente, so it's a policy that is very young in Brazil. Thank you. Don't go in. Thank you. So we have, as I already said, a fragility normative important It's a program of a very important social impact, led by a deputy from the Ministry of Health, And there is a plan, this project, this PL 2583-2020, which is a PL that will solve many of these problems. So we ask our support to the deputado Jorge Sola and to the federal government, because I think that currently is in the Senate. for approval of this process. We have problems contractual, Igor falou de uma coisa importante, que é uma portaria do Ministério, ... orienta how to calculate what is referring to transfer technology, because this impacts a lot on the price. And those contracts, I think that these contracts, from now on, will improve a lot. There are several lacunas in this issue of transfer technology, of the prazos and of punitions for those PDPs that are not carried out until the end. The governance and the institutional governance are still very fragile. We have 24 public laboratories that have very different formats, but the Ministry of Health, with the TCU, are doing a effort for a better governance. And we are implementing this in Bahia Farma, We had problems, first the discontinued PDPs, the government had to do it, the health complex economic and industrial health simply stopped to exist, and in the return, had to reconstruct everything, we had a slow process, and we had to pay for the previsibility of the for the PDPs, for the project of PDP. There is a discontinuity and insecurity of public policies, happened this in Bahia Farma, as George Sola said, we had two PDPs approved, Sevelama and Carvergolina, which were then removed without any technical motivation for other laboratories, this is also a fragility of this policy. A question we have already had fragility in the selection of strategic products. We saw that many projects were presented and not approved by not representing a drug or a strategy for the Ministry of Health. This is a final, we need to do more. And we have issues economic and priceification. has to have a big weight in this price. We already saw that we already started to offer the medicament by a lower price. And sometimes, when it ends up the PDP, it's all the difficulty of the laboratory continuing to sell it for the minister and concorrer, sometimes, with the same laboratory that transferred the technology. So, all these things we need to remember to equate and grow this policy so important for the SUS and Brazil. you know? That's what I wanted to say. We also have a partnership with a Chinese company, a HotGen, for several fast tests, which we have already registered in Anvisa, but we have a great difficulty. We participated in a solicitation, for you to know, the price that gained the solicitation was the price of the transport of the kit, international do kit. So it's very difficult to do this concorrens, and we have to take into consideration that we will learn to do kit, which is extremely important for the Brazil. But we're trying to equate these things with the help of the economic complex, the people of SECTICS, DECIS, etc. I'd like to thank you again and I'm here to be here for any question.